Female pelvic pain and dyspareunia · Review · 2023
Does shockwave help women who have pain during sex?
This review of physiotherapy treatments for painful sex included one shockwave trial of 62 women. That trial, which compared shockwave once a week for four weeks with sham, reported lower pain levels and less pain during sex after shockwave. The review did not include the trial's scores.
- studies of physiotherapy treatments
- 19
- trial tested shockwave against sham
- 1
- women in that trial
- 62
Good to know: Shockwave was one small part of a wider review of 19 studies. The trial checked results up to three months after treatment; the review gave no scores.
Fernández-Pérez P, Leirós-Rodríguez R, Marqués-Sánchez MP, et al. BMC Women's Health, 2023 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
What the trials used
- Extracorporeal shockwave therapy for dyspareunia
- Hurt et al. (2021) was an RCT comparing extracorporeal shockwave therapy with sham in 62 women; treatment lasted 4 weeks at one session per week (Table 2). The Results text adds 4,000 pulses a week, with the transducer moved every 500 pulses over eight areas covering the vulva and perineum; the sham used a pad that blocked transmission to the skin. Device, focused/radial modality, energy flux density, frequency and group sizes are not given. Do not infer settings.
Who took part
Women with pain during sex; the one shockwave trial enrolled 62 women.
Side effects
The review did not report side effects for the shockwave trial.
All the numbers and the full appraisal
Every reported result
What the full paper reports.
Women with dyspareunia; 19 studies were included across multimodal physiotherapy, electrotherapy, massage, interdisciplinary care, pelvic-floor training and one RCT of extracorporeal shockwave therapy. The shockwave RCT enrolled 62 women.
Marinoff Dyspareunia Scale (dyspareunia) and visual analogue scale (pain intensity); the review gives no scores1 reported outcome
Pain and dyspareunia after ESWT versus sham
Marinoff Dyspareunia Scale (dyspareunia) and visual analogue scale (pain intensity); the review gives no scores No numerical between-group estimate reported
Table 3 states that the RCT reported reduced pain intensity and dyspareunia after ESWT. The Results text says the Marinoff Dyspareunia Scale and the pain VAS changed significantly after the intervention and up to three months later in the shockwave group, with no significant change in the placebo group; these are within-group results. The review gives no group scores or between-group effect, so this should not be read as a quantified treatment advantage.
Analysis details and source
This systematic review did not pool an ESWT-specific estimate. Table 5 rates the pain evidence across four RCTs (456 participants) as "Moderate" (⨁⨁◯◯), while the Results text calls the certainty for pain low; either way, the pooled pain result is described for electrotherapy-based interventions and is not ESWT-specific.
How treatment was delivered
Hurt et al. (2021) was an RCT comparing extracorporeal shockwave therapy with sham in 62 women; treatment lasted 4 weeks at one session per week (Table 2). The Results text adds 4,000 pulses a week, with the transducer moved every 500 pulses over eight areas covering the vulva and perineum; the sham used a pad that blocked transmission to the skin. Device, focused/radial modality, energy flux density, frequency and group sizes are not given. Do not infer settings.
The review does not report adverse events for the shockwave RCT. Lack of reporting is not evidence that harms did not occur.
The review included heterogeneous dyspareunia populations and interventions; diagnostic methods and protocols varied. Only one RCT evaluated ESWT; the review names its scales (Marinoff Dyspareunia Scale, pain VAS) and its follow-up (up to three months) but gives no group scores or effect estimate. The reported GRADE table pools pain across four RCTs and cannot be attributed to ESWT.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- The review included heterogeneous dyspareunia populations and interventions; diagnostic methods and protocols varied. Only one RCT evaluated ESWT; the review names its scales (Marinoff Dyspareunia Scale, pain VAS) and its follow-up (up to three months) but gives no group scores or effect estimate. The reported GRADE table pools pain across four RCTs and cannot be attributed to ESWT.
Source-linked critical reading
Systematic review with meta-analysis
Technical source record
Read complete article, all five tables including ESWT trial protocol/results and GRADE summary, two figure captions, methods, study selection, intervention results, discussion, limitations and conclusion. Checked that ESWT-specific numerical effects were not supplied.
One small trial reported improvement after shockwave therapy that was still present three months later, but this review did not provide enough numerical data to compare it reliably with sham or to judge harms.
In women with dyspareunia, what effects do physical therapy interventions have on pain, sexual function and pelvic-floor outcomes?
Systematic review and meta-analysis registered in PROSPERO (CRD42021236155); searches in five databases were conducted in May 2023. Nineteen studies were included; designs included RCTs and nonrandomized/quasi-experimental studies.
The review included women with dyspareunia, but samples varied and some studies enrolled women with other diagnoses. Only one included RCT specifically tested ESWT, enrolling 62 women.
The Hurt et al. RCT compared extracorporeal shockwave therapy with sham for four weeks, one session weekly. The review's text adds 4,000 pulses a week over eight vulvar and perineal areas and a sham pad that blocked transmission; device, energy and modality were not reported.
The comparator was sham shockwave therapy. The review’s broader interventions and comparators were heterogeneous and not combined into a common ESWT network.
The review considered pain, sexual function, muscle properties and quality of life. Its Table 3 says the ESWT RCT reported reduced pain intensity and dyspareunia, but provides no scale-specific score or between-group estimate.
The single ESWT trial’s result is qualitative in this review; no effect size or confidence interval is available. The Results say only that the changes were significant up to three months in the shockwave group and not in the sham group. The Discussion adds that the best reductions in dyspareunia severity came with multimodal physiotherapy and with shockwave; that is a cross-study judgment with no figures and no between-group estimate. Overall pooled GRADE ratings for pain across four RCTs cannot be assigned to ESWT.
No ESWT-specific adverse-event result was reported. The review’s silence does not establish safety.
Interventions and populations varied, only one RCT tested ESWT, its quantitative results were not reproduced, and the review gave only part of the treatment settings (pulse count, treated areas) and no scores for its follow-up of up to three months. The review itself notes low certainty overall.
These results concern women with dyspareunia and cannot be generalized to other pain conditions. The available review summary is insufficient to estimate the size of any ESWT benefit or whether it lasts beyond three months.
Future adequately powered trials should report validated pain and sexual-function scales, group denominators, shockwave settings, follow-up after treatment and adverse events, and should distinguish dyspareunia subtypes.
Read the original article.
Effectiveness of physical therapy interventions in women with dyspareunia: a systematic review and meta-analysis.
Fernández-Pérez P, Leirós-Rodríguez R, Marqués-Sánchez MP, Martínez-Fernández MC, de Carvalho FO, Maciel LYS. · BMC women's health · 2023
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →